FDA’s New Neuroscience Initiative Highlights the Importance of Early, Adaptive Patent Strategy
Key Takeaway: The FDA’s new neuroscience initiative is designed to accelerate a new wave of biotechnology innovation, and with it, new opportunities for intellectual property protection. For companies developing neuroscience...
GSA’s New AI Clause Is Now in Effect: What AI Vendors and Investors Need to Know
Key Takeaways: The U.S. General Services Administration’s (GSA) new AI clause gives the government ownership of fine-tuned model weights and other custom developments built from government data under GSA large...
FDA Announces New Rare Disease Framework With Potential Implications for IP Strategy
Key Takeaway: On October 14, 2026, the FDA announced a proposed framework for rare disease drug development that aims to provide greater regulatory flexibility and disease-tailored evaluation. Increased regulatory clarity...
Subscribe for News and Updates